Related Experiment Video
Updated: May 8, 2026
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine
Yuan Meng1,2,3, LiLi Zhang1,2,3, Jie Yang1,2,3
1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Changling Road No. 88, Xiqing District, Tianjin, 300381, China.
Abstract:
Gastric cancer is a highly heterogeneous disease, with substantial variations observed among patients in clinical manifestation, histological characteristics, and drug sensitivities. Achieving precision medicine necessitates a comprehensive understanding of the molecular mechanisms underlying gastric cancer and the establishment of robust preclinical models. Organoids, cultivated from cancer cells within tumor tissues, utilizing three-dimensional tissue culture techniques, faithfully replicate the features and heterogeneity of in vivo tumors and have emerged as a promising platform. This review explores the application of gastric cancer-derived organoids (GCOs) in preclinical research and clinical translation, highlighting current challenges and outlining future prospects. Although this technology remains some distance from direct clinical application, it holds tremendous potential for clinical utilization.
Insights
Gastric cancer organoids offer a promising preclinical model to study tumor heterogeneity and guide precision medicine. While challenges remain, this 3D culture technology shows significant potential for future clinical applications in cancer treatment.
Area of Science:
- Oncology
- 3D tissue culture
- Cancer biology
Background:
- Gastric cancer exhibits significant patient-to-patient heterogeneity in clinical and molecular aspects.
- Precision medicine requires deep understanding of gastric cancer mechanisms and effective preclinical models.
- Organoids derived from tumors faithfully replicate in vivo characteristics and heterogeneity.
Purpose of the Study:
- To review the application of gastric cancer-derived organoids (GCOs) in preclinical research.
- To explore the potential of GCOs for clinical translation.
- To highlight current challenges and future prospects of GCO technology.
Main Methods:
- Review of current literature on gastric cancer organoid research.
- Analysis of 3D tissue culture techniques for organoid development.
- Evaluation of GCOs for modeling tumor heterogeneity and drug sensitivity.
Main Results:
- Gastric cancer-derived organoids (GCOs) successfully recapitulate the molecular and histological features of primary tumors.
- GCOs demonstrate utility in predicting patient response to various cancer therapies.
- Organoid technology provides a platform for personalized drug screening and discovery.
Conclusions:
- Gastric cancer organoids are valuable tools for advancing preclinical research and understanding disease heterogeneity.
- Despite current limitations, GCOs hold substantial promise for future clinical applications in personalized gastric cancer treatment.
- Further development is needed to bridge the gap between organoid technology and routine clinical practice.
More Related Videos
04:49Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021
08:45Author Spotlight: Generation of and Comparison Between Patient-Derived Gastric Organoids from Different Regions of the Stomach
Published on: January 26, 2024
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...